Elan revenues on the up

Pharmaceuticals company Elan has said its revenues strongly increased (to $526m, or €370m) in the first six months of the year.

Revenues were up by 14%, led by a 30% increase in revenues from multiple-sclerosis drug Tysabri and a 10% increase in revenues from Elan Drug Technologies (EDT).